Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Sodium Hyaluronate Gel Versus Lidocaine Cream for Endotracheal Tube Lubrication (SHG vs LC)

18. november 2026 oppdatert av: Yi Duan, Beijing Tsinghua Chang Gung Hospital

Superiority of Sodium Hyaluronate Gel Over Lidocaine Cream for Endotracheal Tube Lubrication in Reducing Postoperative Throat Numbness: A Randomized Controlled Trial

This study is a prospective, randomized, single-blind, parallel-group, single-center clinical trial in adults undergoing elective laparoscopic surgery under general anesthesia with endotracheal intubation. It will compare sterile medical sodium hyaluronate gel with lidocaine cream as a lubricant applied to the distal portion and cuff surface of the endotracheal tube. The study aims to evaluate whether sodium hyaluronate gel is superior to lidocaine cream in reducing postoperative throat numbness. The primary outcome is throat numbness assessed using a visual analog scale (VAS) 30 minutes after surgery. Secondary outcomes include throat numbness at other specified time points, coughing during emergence and after the first oral water intake, postoperative sore throat, hoarseness, endotracheal tube cuff pressure, hemodynamic responses during intubation and extubation, satisfaction, and adverse events. A total of 120 participants are planned, with 60 participants in each group.

Studieoversikt

Studietype

Intervensjonell

Registrering (Antatt)

120

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 65 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Adults aged 18 to 65 years, of either sex.
  • American Society of Anesthesiologists (ASA) physical status I or II.
  • Patients scheduled for elective laparoscopic surgery under general anesthesia with endotracheal intubation.
  • Expected surgical duration of 1 to 4 hours.
  • Able to understand the study and provide written informed consent.

Exclusion Criteria:

  • Patients expected to be transferred to the intensive care unit (ICU) postoperatively.
  • Known or anticipated difficult airway.
  • History of severe respiratory disease, such as asthma or chronic obstructive pulmonary disease.
  • High risk of gastroesophageal reflux or aspiration, including a full stomach or a history of severe gastroesophageal reflux disease.
  • Known allergy to sodium hyaluronate, lidocaine, or any other study-related medication/product.
  • Pre-existing sore throat or hoarseness before surgery.
  • Pregnancy or breastfeeding.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Forebygging
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Trippel

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Medical sodium hyaluronate lubricating gel

A volume of 2-3 mL of sterile medical sodium hyaluronate lubricating gel (manufacturer identified in the protocol as Bloomage Biotechnology) will be evenly applied to the distal end and cuff surface of the endotracheal tube before intubation.

A volume of 2-3 mL of sterile medical sodium hyaluronate lubricating gel (manufacturer identified in the protocol as Bloomage Biotechnology) will be evenly applied to the distal end and cuff surface of the endotracheal tube before intubation. The protocol lists medical device registration certificate number

Aktiv komparator: Lidocaine cream

A volume of 2-3 mL of lidocaine cream will be evenly applied to the distal end and cuff surface of the endotracheal tube before intubation.

A volume of 2-3 mL of lidocaine cream will be evenly applied to the distal end and cuff surface of the endotracheal tube before intubation.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Throat numbness intensity
Tidsramme: 30 minutes after extubation

Throat numbness intensity will be assessed using the 11-point Visual Analogue Scale (VAS), ranging from 0 to 10. A score of 0 indicates no throat numbness, whereas a score of 10 indicates the most severe imaginable throat numbness. Higher scores indicate more severe throat numbness.

30 minutes after extubation

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Throat numbness intensity
Tidsramme: Immediately after extubation, 1 hour, 8 hours, 16 hours, and 24 hours.

Throat numbness intensity will be assessed using the 11-point Visual Analogue Scale (VAS), ranging from 0 to 10. A score of 0 indicates no throat numbness, whereas a score of 10 indicates the most severe imaginable throat numbness. Higher scores indicate more severe throat numbness.

Immediately after extubation, 1 hour, 8 hours, 16 hours, and 24 hours.
Time to first oral water intake and incidence of coughing during the first water intake
Tidsramme: From extubation to the first oral water intake, within 24 hours after extubation.

The time from extubation to the first oral water intake will be recorded in minutes. The occurrence of coughing during the first water intake will also be recorded.

From extubation to the first oral water intake, within 24 hours after extubation.
Severity of coughing during emergence from general anesthesia
Tidsramme: During emergence from general anesthesia, from the end of anesthesia to 5 minutes after extubation.

Coughing during emergence and extubation will be graded as follows: 0 = no cough; 1 = mild, single cough; 2 = moderate, more than one cough with a duration of less than 5 seconds; 3 = severe, cough lasting more than 5 seconds. Suctioning during emergence will be recorded. No routine suctioning will be performed at extubation or during the first 5 minutes after extubation, unless clinically required.

During emergence from general anesthesia, from the end of anesthesia to 5 minutes after extubation.
Postoperative sore throat severity
Tidsramme: Immediately after extubation, and at 30 minutes, 1 hour, 8 hours, 16 hours, and 24 hours after extubation.

Postoperative sore throat severity will be assessed using the 11-point Visual Analogue Scale (VAS), ranging from 0 to 10. A score of 0 indicates no sore throat, whereas a score of 10 indicates the most severe imaginable postoperative sore throat. Higher scores indicate more severe sore throat.

Immediately after extubation, and at 30 minutes, 1 hour, 8 hours, 16 hours, and 24 hours after extubation.
Postoperative hoarseness severity
Tidsramme: Immediately after extubation, and at 30 minutes, 1 hour, 8 hours, 16 hours, and 24 hours after extubation.

Postoperative hoarseness severity will be assessed using the 11-point Visual Analogue Scale (VAS), ranging from 0 to 10. A score of 0 indicates no hoarseness , whereas a score of 10 indicates the most severe imaginable postoperative sore throat. Higher scores indicate more severe hoarseness .

Immediately after extubation, and at 30 minutes, 1 hour, 8 hours, 16 hours, and 24 hours after extubation.
Endotracheal tube cuff pressure measured in cmH₂O
Tidsramme: At 1, 2, and 3 hours after intubation, and immediately before extubation.

Endotracheal tube cuff pressure will be measured using a cuff pressure manometer. The pressure will be recorded in cmH₂O.

At 1, 2, and 3 hours after intubation, and immediately before extubation.
Incidence of hemodynamic abnormalities assessed by heart rate and blood pressure measurements
Tidsramme: During tracheal extubation

Heart rate (HR), systolic blood pressure (SBP), and diastolic blood pressure (DBP) will be monitored and recorded. Hemodynamic abnormalities are defined as HR greater than 100 beats/min or less than 60 beats/min; SBP ≥140 mmHg and/or DBP ≥90 mmHg; or a decrease in SBP of more than 20% from baseline.

During tracheal extubation
Anesthesiologists' satisfaction with the assigned endotracheal tube lubricant
Tidsramme: Immediately after tracheal intubation.

Anesthesiologists' satisfaction with the assigned lubricant will be evaluated using a 5-point Likert scale, with scores ranging from 1 (very dissatisfied) to 5 (very satisfied). Higher scores indicate greater satisfaction.

Immediately after tracheal intubation.
Patient satisfaction with the anesthesia recovery process
Tidsramme: Within 2 hours after completion of surgery, during the post-anesthesia care unit (PACU) stay and before PACU discharge.

Patient satisfaction with the anesthesia recovery process will be assessed using a 5-point Likert scale during the PACU stay. Scores range from 1 (very dissatisfied) to 5 (very satisfied), with higher scores indicating greater satisfaction.

Within 2 hours after completion of surgery, during the post-anesthesia care unit (PACU) stay and before PACU discharge.
Incidence of adverse events associated with the study interventions
Tidsramme: From administration of the assigned lubricant until 24 hours after extubation.

The occurrence of adverse events, including allergic reactions, laryngospasm, aspiration, nausea, and vomiting, will be recorded and compared between the two groups.

From administration of the assigned lubricant until 24 hours after extubation.

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

4. november 2026

Primær fullføring (Antatt)

4. mars 2027

Studiet fullført (Antatt)

10. mars 2027

Datoer for studieregistrering

Først innsendt

3. november 2026

Først innsendt som oppfylte QC-kriteriene

18. november 2026

Først lagt ut (Faktiske)

20. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

20. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

18. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

UBESLUTTE

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere